Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRISA 018 TAF Implant Trial
PACTR201809520959443Phase 1Unknown
- Sponsor
- CAPRISA
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by CAPRISA. Primary endpoint: Safety as assessed by mean percentage change in creatinine clearance from baseline. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201809520959443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201809520959443.